From 2000 to 2004, 152 patients with multiple myeloma aged p65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34 þ cells collected was similar in the two groups as was the percentage of patients yielding X4 Â 10 6 cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program. Bone Marrow Transplantation (2005) 36, 951-954.
From 2000 to 2004, 152 patients with multiple myeloma aged p65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34 þ cells collected was similar in the two groups as was the percentage of patients yielding X4 Â 10 6 cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program. High-dose melphalan with peripheral blood stem cell (PBSC) rescue represents the standard therapy for patients with newly diagnosed multiple myeloma (MM). [1] [2] [3] [4] [5] [6] The use of autologous PBSC has reduced the incidence of transplant-related mortality in MM by shortening the period of neutropenia and lowering the number of severe infections. 7, 8 The most common regimen for mobilizing PBSC, high-dose cyclophosphamide (4-7 g/m 2 ) followed by granulocyte colony-stimulating factor (G-CSF), is burdened by considerable hematological and extra-hematological toxicity, does not have significant antitumor activity, [8] [9] [10] [11] and between 20 and 30% of patients fail to mobilize adequate numbers of hematopoietic stem cells into the peripheral circulation (the so-called poor mobilizers). Therefore, more intensive regimens with stronger anticancer effects and greater mobilizing capacity, such as DICEP and DHAP, have been investigated; the results have been positive, but the feasibility of using these regimens is often limited by their toxicity. [12] [13] [14] [15] We previously demonstrated that, compared to highdose cyclophosphamide, an infusional regimen of DCEP (dexamethasone, and continuous infusions of cyclophosphamide, etoposide, and cisplatin) is more effective at mobilizing PBSC, has better antitumor activity, is associated with less toxicity and reduces the need for hospitalization. [16] [17] [18] [19] [20] In January 2003, we designed a new DCEP schedule (DCEP-short) that is administered over a shorter period in order to allow complete outpatient management during the mobilization phase.
In this study we retrospectively compare the efficacy of PBSC mobilization and the toxicity of the two mobilizing regimens: infusional-DCEP and DCEP-short.
Patients and methods
From January 2000, 152 MM patients aged p65 years were enrolled in our Institution in two consecutive high-dose programs that included a debulking phase with two courses of pulse-VAD followed by two cycles of stem cell mobilization with the aim of harvesting a total of at least 8 Â 10 6 CD34 þ cells/kg in order to support two autologous transplants. Written informed consent for the procedure was obtained from all patients.
PBSC mobilization
The first 106 patients (group I) received two cycles of infusional-DCEP scheduled as follows: i. G-CSF was administered at a daily dose of 5 mg/kg starting 48 h after the end of chemotherapy until the last day of leukapheresis, both after the infusional-DCEP and the DCEP-short regimens. PBSC were collected with a continuous-flow blood cell separator (Spectra, COBE BCT), processing a total of 2-3 blood mass volumes per leukapheresis. The first PBSC collection was performed when the number of peripheral blood CD34 þ cells was 420/mm 3 with the aim of collecting a minimum of 4 Â 10 6 CD34 þ cells/kg after each DCEP cycle. Patients who yielded less than 2 Â 10 6 CD34 þ cells/kg were considered poor mobilizers. Table 1 shows the characteristics of the patients at time of the first mobilization. As can be seen, the patients in the two groups had similar characteristics.
Flow cytometry
Aliquots of the leukapheresis products were incubated with phycoerythin-conjugated monoclonal anti-CD34 (HPCA2, Becton Dickinson) for 15 min at 201C, then lysed with a lyse-no-wash standard solution and finally incubated for 10 min at 41C. Cells were processed with a FACSort analyzer (Becton Dickinson). Data acquisition was performed with Cellquest software (Becton Dickinson).
Cryopreservation
Cells, diluted in dimethylsulfoxide (DMSO) solution at a final DMSO concentration of 10%, were frozen at a controlled rate in a KRYO II Series freezer (Planer R203) and then stored at À1601C in the liquid phase of nitrogen until use.
Evaluation of tumor response
The clinical response of the patients was assessed after two cycles of DCEP, prior to transplantation. The response criteria were defined as follows: complete response (CR), the absence of M component in serum and urine by immunofixation and o5% plasma cells in a bone marrow aspirate; very good partial response (VGPR), 90% decrease of serum and urine paraprotein level; partial response (PR), at least 50% decrease of serum paraprotein level and 90% decrease of Bence Jones protein; stable disease (SD), less than 25% decrease of serum paraprotein level and Bence Jones protein; progressive disease, no variation or increase of serum or urine paraprotein level.
Statistical analysis
Categorical variables were summarized as counts and relative frequencies, while numerical variables were summarized as medians and ranges. Pearson's w 2 test and, when possible, Fisher's exact test were used to compare the distribution of categorical variables (eg stage and disease status at mobilization, previous alkylating chemotherapy, CD34 þ count X2 Â 10 6 or X4 Â 10 6 /kg and all toxicity parameters) between treatment groups. Tests for significant between-group differences in numerical variables (eg months from first treatment to mobilization, days from start of chemotherapy to first apheresis, CD34 þ cell count) were performed using non parametric one-way analysis of variance techniques, namely the Kruskal-Wallis ANOVA by ranks test. The level of statistical significance of P-values was set at 0.05. All computations and analyses were performed using STATISTICA for Windows 5.5, StatSoft Inc. (2000).
Results

PBSC mobilization
For the comparisons, we considered the results relative to the first PBSC mobilization, since stem cells were not collected after the second DCEP if the number of PBSC harvested after the first DCEP was sufficient for two transplant procedures (ie, 48 Â 10 6 CD34 þ cells/kg). Table 2 shows the characteristics of the PBSC collections.
The median number of CD34 þ cells collected was higher in group II (6.98 Â 10 6 CD34 þ cells/kg) than in group I (5.2 Â 10 6 CD34 þ cells/kg) but the difference was not statistically significant (P ¼ 0.13). There was a limited 
Antitumor efficacy
Response rates before transplantation in the two groups were similar (P ¼ 0.8), with a large number of patients in both groups achieving good quality responses. In detail, response rates in group I were as follows: CR 8.5% (nine patients), VGPR 29.5% (32 patients), and PR 34% (36 patients); 20 patients (19%) had stable disease and nine (8.5%) had progressive disease. The corresponding response rates in group II were: CR 7% (three patients), VGPR 33% (16 patients), and PR 40% (19 patients); five patients (11%) had stable disease and three (7%) had progressive disease. Table 3 summarizes the toxic effects in the two groups. WHO grade III neutropenia (granulocytes o1000/mm 3 ) developed in 12 patients (11%) in group I and in 11 patients (25%) in group II, which was not a statistically significant difference (P ¼ 0.21). The percentage of patients requiring hospitalization because of severe infections was not different in the two groups (five patients (4.7%) in group I vs two patients (4.5%) in group II), and the median time to leukocyte recovery was 2 days (range: 1-6) in both groups.
Toxicity
The incidence of WHO grade II thrombocytopenia (platelets o100 000/mm 3 ) was higher among patients mobilized with DCEP-short than among those who received the infusional-DCEP regimen (14 patients (30%) vs seven patients (6%); P ¼ 0.009). However, only a minority experienced grade III-IV thrombocytopenia. In fact, three patients treated with DCEP-short had grade III (platelets o50 000/mm 3 ) and one grade IV thrombocytopenia (platelets o20 000/mm 3 ) compared to 2 patients and none, respectively, in group I. However, no transfusions were required and no hemorrhagic events occurred in either group. Of note, patients treated with DCEP-short recovered from thrombocytopenia faster (3 days, range 1-10) than those who underwent infusional DCEP (5.5 days, range 3-15), although the difference was not statistically significant. There were no treatment-related deaths in either group.
Discussion
High-dose chemotherapy with PBSC rescue is the treatment of choice for younger patients with MM; 1-7 the mobilization of the hematopoietic stem cells is, therefore, crucial. We previously demonstrated that infusional-DCEP is effective in mobilizing stem cells 18, 19 and has good antitumor activity. 20 However, the drugs in this regimen are administered as a continuous infusion over 4 days, so patients must be hospitalized for a minimum of 4-5 days. We performed this study to evaluate whether a modified, shorter schedule of the DCEP regimen is as effective as the original infusional scheme and whether it has an acceptable Table 2 Characteristics of the PBSC collections in the two groups of patients The mobilizing efficacy of the two schedules was comparable: similar percentages of patients mobilized X2 Â 10 6 /kg CD34 þ cells (90% in group I vs 89% in group II, P ¼ ns) and there were the same proportions of poor mobilizers (10% after infusional-DCEP and 11% after DCEP-short, P ¼ ns). The incidence of grade IV WHO thrombocytopenia was not different in the two groups (none in group I vs one patient in group II) and no patients needed platelet support or had hemorrhagic complications. There was no statistical difference in the incidence of grade II WHO neutropenia after DCEP-short or infusional-DCEP, explaining the low number of patients who developed severe infections requiring hospitalization (4.7% in group I vs 4.5% in group II).
Considering antitumor activity, the DCEP-short regimen had the same efficacy as the original infusional regimen. In fact, 40% of the group II patients achieved good-quality responses (VGPR þ CR) compared with 38% of the group I patients (P ¼ 0.85).
In conclusion, DCEP-short seems to be at least as good as infusional-DCEP in terms of mobilizing efficacy, low toxicity and good antitumor activity. The obvious advantage of this new schedule is that the patients can be managed entirely in an outpatient setting, except for the few individuals who develop severe neutropenia-related infections.
